Empirical Asset Management’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-51,740
Closed -$1.02M 314
2024
Q2
$1.02M Sell
51,740
-19,461
-27% -$369K 0.38% 65
2024
Q1
$1.28M Buy
71,201
+4,739
+7% +$86K 0.62% 38
2023
Q4
$1.13M Sell
66,462
-2,642
-4% -$52.5K 0.92% 26
2023
Q3
$1.37M Buy
69,104
+52
+0.1% +$985 1.2% 20
2023
Q2
$1.3M Buy
69,052
+2,904
+4% +$58.6K 1.15% 22
2023
Q1
$1.35M Buy
66,148
+15,716
+31% +$316K 1.29% 22
2022
Q4
$1.07M Sell
50,432
-3,118
-6% -$64.6K 1.13% 18
2022
Q3
$1.09M Buy
53,550
+1,992
+4% +$39.7K 1.19% 19
2022
Q2
$1.12M Buy
51,558
+8,316
+19% +$168K 1.18% 20
2022
Q1
$793K Buy
43,242
+6,999
+19% +$129K 0.75% 45
2021
Q4
$644K Buy
+36,243
New +$616K 0.62% 55

Other funds holding BTAL

Empirical Asset Management's BTAL Position: Q3 2024 in Review

Empirical Asset Management sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q3 2024, closing a stake of 51,740 shares — an estimated $1.02M sold.

Empirical Asset Management first reported a position in BTAL in Q4 2021 and held it in 11 quarters. The position peaked at $1.37M in Q3 2023. 71 funds tracked by Wall St. Rank hold BTAL as of Q3 2024.

  • Empirical Asset Management reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q3 2024 after selling out during the quarter.
  • Empirical Asset Management sold 51,740 AGF US Market Neutral Anti-Beta Fund shares in Q3 2024, an estimated $1.02M.
  • Empirical Asset Management first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2021 and held it in 11 quarters.
  • Empirical Asset Management's AGF US Market Neutral Anti-Beta Fund position peaked at $1.37M in Q3 2023.
  • 71 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q3 2024.

Based on Empirical Asset Management's 13F filing for Q3 2024, filed 11 Oct 2024.